NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Procept BioRobotics Corporation PRCT
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$308.1M
▲ 37.2% vs FY2024
EPS · FY25
$-1.72
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-24.9%
Net margin · FY25
-31.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 308.1M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 31 cents on every revenue dollar this year.
Per share
USD -1.72
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-24.9%
Return on equity, FY2025
ROE
Operating margin-33.7%
Net margin-31.0%
Return on assets-18.3%
Each USD of equity lost 25 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+109.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+60.1%
+109.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 508.1M
total assets, end of FY2025
Total assetsUSD 508.1M
EquityUSD 365.9M
CashUSD 286.5M
Gross debtUSD 51.6M
Net debtUSD -234.9M
Current ratio6.85×
The company holds more cash than debt.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.3
0.2
0.1
0.1
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−1.72
−1.75
−2.24
−1.96
−3.63
−14.47
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−24.9
−26.8
−44.3
−37.6
−142.2
·
Shares out B
0.06
0.05
0.05
·
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed